Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce ...
The Rocky Mountain chain is a fascinating geologic formation, as it (at least, at first glance) defies some basic geological rules, including that most mountain ranges form subduction zones. A new ...
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
- Acquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectory "The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated ...
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An ...
Sept 30 (Reuters) - Crystalys Therapeutics said on Tuesday it has emerged from stealth mode with a funding round of $205 million to help finance global late-stage trials of its lead drug as a ...
In gout, the drug choices for patients remain limited. The history of this field includes many molecules that fell short in the clinic or on the market for safety reasons. James Mackay knows firsthand ...
Atom Therapeutics is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and safety profile to stand out from the competition. The Chinese biotech evaluated the oral ...
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 ...
Peering through a cosmic keyhole at distant baby star, astronomers may have opened a new window on the deep past of our own solar system. Weighing in at 0.6 solar mass, HOPS-315 should someday grow to ...
The European Alliance of Associations for Rheumatology - recommends that serum urate should be maintained at <6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe gout. But despite ...
Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown. An ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results